Brief: Vital KSK Holdings Inc - Conclusion Of Exclusive License Agreement Of Shield Therapeutics PLC's Iron Deficiency Treatment By Consolidated Subsidiary
22/04/2025 06:32
April 22 (Reuters) - Vital KSK Holdings Inc 3151.T: NOTICE OF CONCLUSION OF EXCLUSIVE LICENSE AGREEMENT OF SHIELD THERAPEUTICS PLC'S IRON DEFICIENCY TREATMENT BY CONSOLIDATED SUBSIDIARY Source text: ID:nTSpv7f01e Further company coverage: 3151.T
Recent news on Shield Therapeutics
See all newsBrief: Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US
Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
Shield Therapeutics - Interim results for the six months ended 30 Jun 26
Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
Shield Therapeutics - Q2 and H1 2026 Trading Update